Charles Schwab Investment Management Inc. Raises Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Charles Schwab Investment Management Inc. raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,246,890 shares of the medical research company’s stock after buying an additional 44,991 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.69% of IQVIA worth $245,026,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. FMR LLC lifted its position in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. Cantillon Capital Management LLC increased its stake in shares of IQVIA by 12.3% during the fourth quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock valued at $406,018,000 after purchasing an additional 226,017 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Impax Asset Management Group plc boosted its position in shares of IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after purchasing an additional 157,809 shares in the last quarter. Finally, Nordea Investment Management AB grew its stake in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of several analyst reports. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Stephens started coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Finally, Morgan Stanley boosted their price objective on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Trading Down 0.2 %

Shares of NYSE:IQV opened at $185.45 on Friday. The stock’s 50-day simple moving average is $197.95 and its two-hundred day simple moving average is $213.47. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market capitalization of $32.70 billion, a price-to-earnings ratio of 24.73, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.